By Javier Hasse and Aaron Bry.
2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.
Businesses around the globe are researching and developing new drugs based on psychedelic properties to support a whole host of conditions. Some of the most active companies to watch boast impressive CEOs to keep an eye on in 2022. Here are a few to watch closely:
Amy Emerson – MAPS Public Benefit Corporation (MAPS PBC)
Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit.
As CEO, Amy has led the growth and development of this subsidiary and is responsible for the overall global regulatory strategy and implementation of research programs. Emerson is focused on the MDMA-assisted psychotherapy program within MAPS PBC.
Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.
Joseph Tucker, Ph.D. – Enveric Biosciences Inc. (NASDAQ: ENVB)
Dr. Tucker is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL) (TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and CEO of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (OTC: CANSF) (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer.
Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.
Connor Haslam – Microdose Psychedelic Insight
With almost a decade of experience in entrepreneurship and creative media pursuits, Connor Haslam brings rich experience and diverse insight into his role as Chief Executive Officer at Microdose. His lifelong advocacy for the therapeutic use of psychedelic medicine is expressed through artful, creative and ethical brand development.
Despite never having had a single cup of coffee Connor has somehow found the energy to …